Bipolar Disorder
Bipolar disorder, characterised by extreme fluctuations in mood, is a complex mental health condition that affects approximately 45 million people worldwide. Current research on psychedelics as a potential treatment is limited due to concerns about inducing manic episodes, but emerging evidence, particularly regarding ketamine, suggests promise for alleviating depressive symptoms associated with the disorder.
Key Insights
- 1
The intricate nature of bipolar disorder complicates treatment, necessitating a combination of psychotherapeutic and pharmacological approaches.
- 2
Research indicates a potential for ketamine to alleviate depressive symptoms in bipolar disorder, although its long-term efficacy remains uncertain.
- 3
Concerns about psychedelics inducing manic episodes have led researchers to approach this treatment area with caution, particularly concerning classic psychedelics like LSD and psilocybin.
- 4
Current clinical trials exploring psychedelics for bipolar disorder, particularly psilocybin, focus on individuals in depressive states, which may mitigate the risk of triggering mania.
- 5
A recognised need for further research into the safe application of psychedelic therapy in bipolar disorder is crucial, especially given the potential interactions with common medications such as lithium.
What is Bipolar Disorder?
Bipolar disorder, previously known as manic-depressive illness, results in significant mood swings ranging from manic highs to depressive lows. The condition adversely affects energy, activity levels, concentration, and daily functioning capabilities.
There are three main classifications of bipolar disorder: bipolar I, characterised by prolonged manic episodes and depressive episodes of at least two weeks; bipolar II, involving patterns of depressive and hypomanic episodes without full-blown manic episodes; and cyclothymic disorder, which presents with periods of hypomanic and depressive symptoms lasting for at least two years.
Symptoms associated with manic episodes include decreased need for sleep, inflated self-esteem, and racing thoughts, while depressive states typically involve persistent sadness, loss of interest, feelings of worthlessness, and recurrent suicidal thoughts.
The aetiology of bipolar disorder remains uncertain, but genetic predisposition, notably having a first-degree relative with the disorder, is a significant risk factor. Diagnosis is often facilitated through structured clinical interviews and standardised assessment scales.
Current Treatments
First-line treatments for bipolar disorder typically encompass psychotherapy modalities such as cognitive behavioural therapy (CBT), interpersonal and social rhythm therapy (IPSRT), and family-focused therapy, often in conjunction with medication like mood stabilisers (e.g., lithium), antipsychotics, and antidepressants.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Bipolar Disorder.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ketamine Significant evidence supports ketamine's efficacy in reducing depressive symptoms in bipolar disorder. | Large | Moderate | Consistent |
| Psilocybin Ongoing clinical trials will provide more data on psilocybin's safety and efficacy in bipolar disorder contexts. | Medium | Low | Inconsistent |
| LSD Current scepticism about LSD's use stems from risks of manic episodes. | None | Very Low | Inconsistent |
Ketamine and Bipolar Disorder
Ketamine is a non-competitive antagonist of the NMDA receptor, generating rapid antidepressant effects that may help stabilize mood in individuals with bipolar disorder. Its unique pharmacological profile allows for the amelioration of depressive symptoms without the serotonergic pathways that traditional psychedelics affect, thereby reducing the risk of inducing mania during treatment.
Psilocybin and Bipolar Disorder
As a classic psychedelic, psilocybin primarily acts as a 5-HT2A agonist, which raises concerns about potential manic episode activation in bipolar patients. Nevertheless, research is cautiously exploring its viability in treating the depressive aspects of bipolar disorder, particularly when administered in controlled settings and during non-manic phases.
Clinical Outlook
As interest in psychedelic research grows, the future may usher in innovative therapies for bipolar disorder leveraging the unique mechanisms of compounds like ketamine and psilocybin. With ongoing trials and a commitment to understanding the nuanced interactions between psychedelics and mood regulation, there is hope for developing effective, safe treatment protocols tailored to individuals with this challenging condition.
Industrial Landscape
Key stakeholders include academic institutions conducting clinical trials, notably the Sheppard Pratt Health System in collaboration with Compass Pathways, as well as various researchers exploring the implications of psychedelics in mood disorders.
Quick Indicators
Related Topics
Organisations
Search →Janssen Research & Development
Janssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
COMPASS Pathways
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
National Institute on Drug Abuse (NIDA)
U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.
Radboud University
Radboud University Medical Center (Radboudumc) is one of the Netherlands' leading academic medical centers, located in Nijmegen. It combines patient care, education, and scientific research under one roof, with a particular strength in neuroscience through its Donders Centre for Medical Neuroscience. Radboudumc is known for its translational research approach. The medical centre bridges fundamental science and clinical practice across areas including oncology, rare diseases, and psychiatry. In the field of psychedelic medicine, Radboudumc has been involved in ibogaine research, conducting studies through its Department of Pharmacology–Toxicology and Department of Psychiatry, examining ibogaine as a potential treatment for opioid use disorder. This work included a clinical study evaluating the cardiac, cerebellar, and psychomimetic safety of ibogaine in opioid-dependent patients, contributing important safety data to the broader scientific understanding of this compound.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
University of California, San Francisco
University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
Integrative Mental Health University
The Integrative Mental Health University (IMHU) is a nonprofit continuing education platform founded by Emma Bragdon PhD in 2013, offering accredited courses for mental health professionals on psychedelic-assisted therapy, spiritual emergence, and integrative healing modalities. IMHU serves clinicians seeking to incorporate psychedelic therapy and spiritual emergency response into their professional practice.
Centre for Addiction and Mental Health
The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health teaching hospital, located in Toronto, Ontario. CAMH is a major hub for psychedelic research in Canada, running trials on psilocybin, MDMA, and ketamine across a range of psychiatric indications.
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation (MRO) headquartered in Madison, Wisconsin. Co-founded in 2014 by Bill Linton (CEO of Promega Corporation) and Malynn Utzinger, M.D., Usona was established after Linton witnessed the profound impact of a Johns Hopkins psilocybin study on a terminally ill friend. Unlike commercial drug developers, Usona operates as a mission-driven MRO — conducting and supporting pre-clinical and clinical research on psilocybin and other consciousness-expanding medicines, with the goal of developing accessible, affordable treatments. Its research leadership includes Dr. Charles Raison (Director of Clinical and Translational Research, UW-Madison psychiatrist) and Dr. Alexander Sherwood (medicinal chemist). Usona's psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study (the largest Phase 2 randomised controlled trial of psilocybin for MDD at the time), the Institute launched the Phase 3 uAspire trial in 2024 — a 240-participant, randomised, double-blind, multicentre study comparing 25 mg psilocybin vs placebo in adults with MDD. Usona is also exploring 5-MeO-DMT in early-stage research.
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai is a leading US academic medical institution home to the Parsons Research Center for Psychedelic Healing, which runs rigorous clinical trials of MDMA- and psilocybin-assisted therapies for PTSD and trauma in veteran and civilian populations.
GH Research
GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dublin, Ireland, developing novel mebufotenin (5-MeO-DMT) therapeutics for treatment-resistant depression, bipolar II disorder, and postpartum depression. Its lead asset GH001 — an inhaled mebufotenin formulation — met the primary endpoint of its Phase 2b TRD trial in February 2025 with striking results: -15.5 point MADRS reduction vs placebo (p<0.0001) and 57.7% remission vs 0%. With a single-day dosing paradigm requiring no structured psychotherapy, GH001 is positioned as a differentiated asset; Phase 3 global initiation is planned for 2026 following FDA clinical hold lift. GH002 (IV mebufotenin) completed Phase 1 in healthy volunteers.
People
Search →Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Kenji Hashimoto
Professor, Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health
He is a leading Japanese psychiatric researcher whose work on ketamine, arketamine, and related biomarkers has helped shape modern rapid-acting antidepressant research.
David Mathai
Psychiatrist and Assistant Professor at The Johns Hopkins University School of Medicine
He is a psychiatric researcher at Johns Hopkins whose work spans psilocybin, ketamine/esketamine, and psychedelic-assisted psychotherapy, with multiple publications on experiential and therapeutic outcomes.
Bing Cao
PhD researcher at the Key Laboratory of Cognition and Personality, Faculty of Psychology, Southwest University
He is a recurring coauthor on multiple ketamine and psychedelic-adjacent systematic reviews and mechanistic studies, making him a visible contributor to contemporary rapid-acting antidepressant research.
Scott Tyler Aaronson
Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt; Adjunct Professor of Psychiatry, University of Maryland School of Medicine
He is a leading psychiatrist in treatment-resistant depression and a key investigator on psilocybin studies, including work on preparation, dosing, outcomes, and mechanisms of psychedelic-assisted therapy.
Mark Andrew Frye
Chair, Department of Psychiatry and Psychology, Mayo Clinic (Rochester, Minnesota)
He is a leading mood-disorders psychiatrist whose work has helped shape the clinical evidence base and consensus guidance for ketamine in depression.
Connected Evidence
The latest clinical data and verified academic findings associated with Bipolar Disorder.